Guía de Práctica Clínica sobre el Diagnóstico, el Tratamiento y la Prevención de la Tuberculosis.

  1. Introducción
  2. Alcance y objetivos
  3. Metodología
  4. Diagnóstico de la tuberculosis
  5. Tratamiento de la tuberculosis
  6. Prevención de la tuberculosis
  7. Difusión e implementación
  8. Estrategias diagnósticas y terapéuticas
  9. Bibliografía

Abre nueva ventana: Bibliografía en versión pdf
Descargar Bibliografía (299 Kb)
Descargar GPC sobre la Tuberculosis (1.935 Kb)

Bibliografía

1. Ministerio de Sanidad y Política Social, editor. Plan para la Prevención y el Control de la Tuberculosis en España [internet]. Madrid; 2008 [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.msps.es.

2. World Health Organization, editor. Global tuberculosis control 2009: epidemiology, strategy, financing [internet]. Switzerland: WHO Press; 2009. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/tb/publications/global_report/en/.

3. Union Internacional contra la Tuberculosis y Enfermedades Respiratorias, editor. Bases epidemiológicas del control de la tuberculosis (traducción al español) [internet]. París: UICTER; 1999. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.theunion.org.

4. Altet MN, Alcaide J, Hernández I. Tabaquismo y tuberculosis: ¿otro dúo maldito?. Prev Tab. 2004;6:113-24.

5. World Health Organization, editor. Guidance for national tuberculosis programmes on the management of tuberculosis in children [internet]. Switzerland: WHO Press; 2009. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/child_adolescent_health/documents/htm_tb_2006_371/en/index.html.

6. Marais BJ, Obihara CC, Warren RM, Schaaf HS, Gie RP, Donald PR. The burden of childhood tuberculosis: a public health perspective. Int J Tuberc Lung Dis. 2005;9:1305-13.

7. Altet MN, Alcaide J. Control y eliminación de la tuberculosis en España: las estrategias para el Siglo XXI. An Pediatr (Barc). 2006;64(1):66-73.

8. World Health Organization, editor. Global tuberculosis control 1997 [internet]. Switzerland: WHO Press; 1997. [consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/tb/publications/global_report/archive/en/index.html.

9. Institut de veille sanitaire, editor. EuroTB and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of Tuberculosis in Europe. Report on Tuberculosis cases notifi ed in 2005 [internet]. France; 2007. [consultado el 19 de Octubre de 2009]. Disponible en: http://www.eurotb.org/rapports/2005/full_report.pdf.

10. E. Rodríguez, G. Hernández, S. Villarrubia, O. Díaz, O. Tello (Área de Vigilancia de la Salud Pública. Centro Nacional de Epidemiología. Instituto de Salud Carlos III.) Casos de tuberculosis declarados a la Red Nacional de Vigilancia Epidemiológica. España, 2008. Ministerio de Ciencia e Innovación. Instituto de Salud Carlos III. Boletín epidemiológico semanal. 2009 Vol. 17 nº 11/121-132. ISSN: 1135-6286.

11. Ríos M, Monleón-Getino T. A graphical study of tuberculosisi incidence and trends in the WHO's European region (1980-2006). Europ J Epidemiol. 2009;24:381-7.

12. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle. 1976;57:275-9.

13. Alcaide J, Altet MN, Salleras L. Vacuna BCG. En: Masson, editor. Vacunaciones preventivas. Principios y aplicaciones. 2ª ed. Barcelona: Elsevier; 2003. Pág. 529-74.

14. Altet MN, de Souza ML, Milá C. Infecciones por Micobacterias. En: Masson, editor. Vacunaciones preventivas. Principios y aplicaciones. 2ª ed. Barcelona: Elsevier; 2003. Pág. 479-515.

15. Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. Personal and Societal Health Quality Lost to Tuberculosis. PLoS ONE. 2009;4(4): e5080.

16. Mitchison DA. Basic mechanisms of chemoteraphy. Chest 1979;76:771-81.

17. Ruiz.ManzanoJ, Blanquer R, Calpe JL, Caminero JA, Caylá J, Dominguez JA, García JM, Vidal R. Normativa SEPAR. Diagnóstico y tratamiento de la tuberculosis. Arch Bronconeumol. 2008;44(10):551-66.

18. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J. 2002;19:765-775.

19. An expanded DOTS Framework for effective tuberculosis control. Int J Tuberc Lung Dis. 2002;6:378-88.

20. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians, 2006.

21. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000. Thorax. 2000;55:887-901.

22. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. Am J Respir Crit Care Med. 2000;161:S221-S247.

23. Grupo de trabajo de Tuberculosis de la Sociedad Española de Infectología Pediátrica (SEIP). Documento de consenso sobre el tratamiento de la exposición a tuberculosis y de la infección tuberculosa latente en niños. An Pediatr (Barc). 2006;64(1): 59-65.

24. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007. Guías de Práctica Clínica en el SNS: I+CS Nº 2006/0I.

25. Schünemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A, et al. ATS Documents Development and Implementation Committee. An offi cial ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006; 174(5):605-14.

26. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test Measurements. Thorax. 2002; 57: 804-9.

27. Centers for Disease Control and Prevention [internet]. Atlanta: CDC [actualizada a 1 Junio de 2009]. Fact Sheets: Tuberculin Skin Testing. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm.

28. Pai M, Zwerling A, Menzies D Systematic Review: T-Cell-based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update. Ann Intern Med. 2008;149:177-84.

29. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146(5):340-54.

30. Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, et al. Comparing QuantiFERON-Tuberculosis Gold, T-SPOT Tuberculosis and Tuberculin Skin Test in HIV-Infected Individuals from a Low Prevalence Tuberculosis Country. AIDS. 2008;22(18):2471-9.

31. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al. Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients with Active Tuberculosis. Chest. 2008; 133(5): 1196-202.

32. Raby E, Moyo M, Devendra A, Banda J, De Haas P, Ayles H, et al. The Effects of HIV on the Sensitivity of a Whole Blood IFN-Gamma Release Assay in Zambian Adults with Active Tuberculosis. PLoS ONE. 2008;3(6): e2489.

33. National Tuberculosis Controllers Association; Center for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis;recomme ndations from The National Tuberculosis Controllers Assotiation and CDC, and Guidelines for using the Quantiferon-TB Gold Test for detecting Mycobacterium tuberculosis Infection, United States. MMWR 2005 Dec 16;54(RR-15):1-55.

34. Brandli O. The clinical presentation of tuberculosis. Respiration. 1998;65(2):97-105.

35. Parimon T, Spitters CE, Muangman N, Euathrongchit J, et al. Unexpected Pulmonary Involvement in Extrapulmonary Tuberculosis Patients. Chest. 2008;134(3):589-94.

36. Wisnivesky JP, Serebrisky D, Moore C, Sacks HS, Iannuzz MC, McGinn T. Validity of Clinical Prediction Rules for Isolating Inpatients with Suspected Tuberculosi. A Systematic Review. J Gen Intern Med. 2005; 20:947-52.

37. Soto A, Solari L, Agapito J, Acuna-Villaorduna C, Lambert ML, Gotuzzo E. Development of a clinical scoring system for the diagnosis of smear-negative pulmonary tuberculosis. Braz J Infect Dis. 2008;12(2):128-32.

38. Solari L, Acuna-Villaorduna C, Soto A, Agapito J, Perez F, Samalvides F. A clinical prediction rule for pulmonary tuberculosis in emergency departments. Int J Tuberc Lung Dis. 2008;12(6): 619-24.

39. Wang CS, Chen HC, Chong IW, Hwang JJ, Huang MS. Predictors for identifying the most infectious pulmonary tuberculosis patient. J Formos Med Assoc. 2008;107(1):13-20.

40. Rakoczy KS, Cohen SH, Nguyen HH. Derivation and validation of a clinical prediction score for isolation of inpatients with suspected pulmonary tuberculosis. Infect Control Hosp Epidemiol. 2008;29(10):927-32.

41. den Boon S, White NW, van Lill SW, Borgdorff MW, Verver S, Lombard CJ. An evaluation of symptom and chest radiographic screening in tuberculosis prevalence surveys. Int J Tuberc Lung Dis. 2006;10(8):876-82.

42. Geng E, Kreiswirth B, Burzynski J, Schluger NW. Clinical and Radiographic Correlates of Primary and Reactivation Tuberculosis A Molecular Epidemiology Study. JAMA. 2005;293: 2740-45.

43. Jones BE, Ryu R, Yang Z, Cave MD, Pogoda JM, Otaya M, et al. Chest radiographic fi ndings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med. 1997;156:1270-73.

44. Gómez-Pastrana D, Carceller-Blanchard A. ¿Debe realizarse una tomografía computarizada torácica a los niños con infección tuberculosa sin enfermedad aparente? An Pediatr (Barc). 2007;67(6):585-93.

45. American Academy of Pediatrics. [Summaries of infectious diseases: Tuberculosis]. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009: [680-701].

46. Marais BJ, Gie RP, Schaaf S, Beyers N, Donald PR, Starke JR. Childhood Pulmonary Tuberculosis. Old Wisdom and New Challenges. Am Respir Crit Care Med. 2006;173:1078-90.

47. Cruz AT, Starke JR. Clinical manifestations of tuberculosis in chidren. Paediatr Respir Rev. 2007;8:107-17.

48. Tuberculosis Coalition for Technical Assistance: International Standards for Tuberculosis Care (ISTC) [internet]. The Hague: Tuberculosis Coalition for Technical Assistance, 2006. [Consultado el 19 de Octubre de 2009]. Disponible en: www.who.int/tb/publications/2006/istc/en.

49. Long R, Ellis E, editors. Canadian Tuberculosis Standards, 6ª ed [internet]. Tuberculosis Prevention and Control, Public Health Agency of Canada, Canadian Lung Association/Canadian Thoracic Society, 2007. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.phacaspc.gc.ca/tbpc-latb/pubs/tbstand07-eng.php.

50. Schoch OD, Rieder P, Tueller C et al. Diagnostic yield of sputum, induced sputum, and bronchoscopy after radiologic tuberculosis screening. Am J Respir Crit Care Med. 2007; 175(1): 80-6.

51. Anderson C, Inhaber N, Menzies D. Comparison of sputum induction with fi ber-optic bronchoscopy in the diagnosis of tuberculosis. Am J Respir Crit Care Med. 1995;152:1570-4.

52. Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis. 2007;44(11):1415-20.

53. Conde MB, Soares SL, Mello FC, Rezende VM, Almeida LL, Reingold AL, et al. Comparison of sputum induction with fi beroptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune defi ciency syndrome reference center in Rio de Janeiro, Brazil. Am J Respir Crit Care Med 2000; 162(6):2238-40.

54. Conde MB, Loivos AC, Rezende VM, Soares SL, Mello FC, Reingold AL, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. Am J Respir Crit Care Med. 2003;167(5): 723-5.

55. Morse M, Kessler J, Albrecht S, Kim R, Thakur R, Nthobatsang R, et al. Induced sputum improves the diagnosis of pulmonary tuberculosis in hospitalized patients in Gaborone, Botswana. Int J Tuberc Lung Dis. 2008;12(11):1279-85.

56. Saglam L, Akgun M, Aktas E. Usefulness of induced sputum and fi breoptic bronchoscopy specimens in the diagnosis of pulmonary tuberculosis. J Int Med Res. 2005;33(2):260-5.

57. Parry CM, Kamoto O, Harries AD, Wirima JJ, Nyirenda CM, Nyangulu DS, et al. The use of sputum induction for establishing a diagnosis in patients with suspected pulmonary tuberculosis in Malawi. Tuber Lung Dis. 1995;76:72-6.

58. Baughman RP, Dohn MN, Loudon RG, Frame PT. Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. Chest. 1991;99(1):92-7.

59. Chen NH, Liu YC, Tsao TC, Wu TL, Hsieh MJ, Chuang ML, et al. Combined bronchoalveolar lavage and polymerase chain reaction in the diagnosis of pulmonary tuberculosis in smearnegative patients. Int J Tuberc Lung Dis. 2002;6(4):350-5.

60. Norrman E, Keistinen T, Uddenfeldt M, Rydstrom PO, Lundgren R. Bronchoalveolar lavage is better than gastric lavage in the diagnosis of pulmonary tuberculosis. Scand J Infect Dis. 1988;20(1):77-80.

61. Rizvi N, Rao NA, Hussain M. Yield of gastric lavage and bronchial wash in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2000;4(2):147-51.

62. Tan YK, Lee AS, Khoo KL, Ong SY, Wong SY, Ong YY. Rapid mycobacterial tuberculosis detection in bronchoalveolar lavage samples by polymerase chain reaction in patients with upper lobe infi ltrates and bronchiectasis. Ann Acad Med Singapore. 1999;28(2):205-8.

63. Tueller C, Chhajed PN, Buitrago-Tellez C, Frei R, Frey M, Tamm M. Value of smear and PCR in bronchoalveolar lavage fl uid in culture positive pulmonary tuberculosis. Eur Respir J. 2005;26(5):767-72.

64. Willcox PA, Benatar SR, Potgieter PD. Use of the fl exible fi beroptic bronchoscope in diagnosis of sputum-negative pulmonary tuberculosis. Thorax. 1982;37:598-601.

65. Chawla R, Pant K, Jaggi OP, Chandrashekhar S, Thukral SS. Fibreoptic bronchoscopy in smear negative pulmonary tuberculosis. Eur Respir J. 1998;1:804-806.

66. Charoenratanakul S, Dejsomritrutai W, Chaiprasert A. Diagnostic role of fi beroptic bronchoscopy in suspected smear negative pulmonary tuberculosis. Respir Med. 1995;89(9):621-3.

67. Schoch OD, Rieder P, Tueller C et al. Diagnostic yield of sputum, induced sputum, and bronchoscopy after radiologic tuberculosis screening. Am J Respir Crit Care Med. 2007; 175(1): 80-6.

68. Wongthim S, Udompanich V, Limthongkul S, Charoenlap P, Nuchprayoon C. Fiberoptic bronchoscopy in diagnosis of patients with suspected active pulmonary tuberculosis. J Med Assoc Thai. 1989;72:154-9.

69. Berggren-Palme I, Gudetta B, Bruchfeld J, Eriksson M, Giesecke J. Detection of Mycobacterium tuberculosis in gastric aspirate and sputum collected from Ethiopian HIV-positive and HIV-negative children in a mixed in- and outpatient setting. Acta Paediatr. 2004;93(3):311-5.

70. Abadco DL, Steiner P. Gastric lavage is better than bronchoalveolar lavage for isolation of Mycobacterium tuberculosis in childhood pulmonary tuberculosis. Pediatr Infect Dis J. 1992; 11(9):735-8.

71. Gomez-Pastrana D, Torronteras-Santiago R, Caro-Mateo P, et al. [Effectiveness of smears and cultures in gastric aspirate samples in the diagnosis of tuberculosis]. An Esp Pediatr. 2000;53(5):405-11.

72. Laven GT. Diagnosis of tuberculosis in children using fl uorescence microscopic examination of gastric washings. Am Rev Respir Dis. 1977;115(5):743-9.

73. Shata AM, Coulter JB, Parry CM, Ching'ani G, Broadhead RL, Hart CA. Sputum induction for the diagnosis of tuberculosis. Arch Dis Child. 1996;74(6):535-7.

74. Singh M, Moosa NV, Kumar L, Sharma M. Role of gastric lavage and broncho-alveolar lavage in the bacteriological diagnosis of childhood pulmonary tuberculosis. Indian Pediatr. 2000;37(9):947-51.

75. Somu N, Swaminathan S, Paramasivan CN et al. Value of bronchoalveolar lavage and gastric lavage in the diagnosis of pulmonary tuberculosis in children. Tuber Lung Dis. 1995; 76(4): 295-9.

76. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confi rmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet. 2005;365:130-4.

77. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006; 6:570-81.

78. Van Deun A, Chuquiyauri R, Torrea G, Agapito J, Verdonck K, Gotuzzo E. Yield of fl uorescence microscopy versus culture for tuberculosis at a middle-income country referral hospital. Trans R Soc Trop Med Hyg. 2008;102(6):564-9.

79. Steingart KR , Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664-74.

80. WHO, IUATLD, Royal Netherlands Tuberculosis Association. Revised international defi nitions in tuberculosis control. Int J Tuberc Lung Dis. 2001;5(3):213-5.

81. Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007;11(5):485-95.

82. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, Drobniewski F, Lalvani A. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess. 2007;11(3):1-196.

83. Domínguez J, Blanco S, Lacoma A, García-Sierra N, Prat C, Ausina V. Utilidad de la biología molecular en el diagnóstico microbiológico de las infecciones por micobacterias. Enferm Infecc Microbiol Clin. 2008;Suppl 9:33-41.

84.Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplifi cation tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE. 2008;3(2):e1536.

85. Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Miller WC. Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis. J Clin Microbiol. 2003;41(7): 3233-40.

86. Kalantri S, Pai M, Pascopella L, Riley L, Reingold A. Bacteriophage- based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systematic review and metaanalysis. BMC Infect Dis. 2005;5:59.

87. Alcaide F, Galí N, Domínguez J, Berlanga P, Blanco S, Orús P, et al. Usefulness of a new mycobacteriophage-based technique for rapid diagnosis of pulmonary tuberculosis. J Clin Microbiol. 2003;41(7):2867-71.

88. Steingart KR, Henry M, Laal S, Hopewell PC, Ramsay A, Menzies D, et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med. 2007;4(6):e202.

89. Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest. 2004;125:987-9.

90. Liang QL, Shi HZ, Wang K, Qin SM, Qin XJ. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med. 2008;102(5):744-54.

91. Greco S, Girardi E, Masciangelo R, Capoccetta GB, Saltini C. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis. 2003;7(8):777-86.

92. Goto M, Noguchi Y, Koyama H, Hira K, Shimbo T, Fukui T. Diagnostic value of adenosine deaminase in tuberculous pleural effusion: a meta-analysis. Ann Clin Biochem. 2003; 40: 374- 381.

93. Morisson P, Neves DD. Evaluation of adenosine deaminase in the diagnosis of pleural tuberculosis: a Brazilian meta-analysis. J Bras Pneumol. 2008;34(4):217-24.

94. Ena J, Valls V, Pérez de Oteyza C, Enríquez de Salamanca R. Utilidad y limitaciones de la adenosina desaminasa en el diagnóstico de la pleuresía tuberculosa. Estudio metaanalítico. Med Clin (Barc). 1990; 95:333-5.

95. Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine Deaminase Activity is a Sensitive Marker for the Diagnosis of Tuberculous Pleuritis in Patients with very Low CD4 Counts. PLoS ONE. 2008;3(7):e2788.

96. Jiang J, Shi HZ, Liang QL Qin SM, Qin XJ. Diagnostic Value of Interferon gamma in Tuberculous Pleurisy. A Metaanalysis. Chest. 2007;131:1133-41.

97. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM Jr. Nucleic acid amplifi cation tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis. 2004;23:4:6.

98. Pai M, Flores LF, Pai N, Hubbard A, Riley LW, Colford JM. Diagnostic accuracy of nucleic acid amplifi cation tests for tuberculous meningitis: A systematic review and meta-analysis. Lancet Infect Dis. 2003;3:633-43.

99. Chen X, Yang Q, Zhang M, Graner M, Zhu X, Larmonier N, et al. Diagnosis of active tuberculosis in China using an in-house gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol. 2009;16(6):879-84.

100. Tuon FF, Litvoc MN, Lopes MI. Adenosine deaminase and tuberculous pericarditis: a systematic review with meta-analysis. Acta Trop. 2006;99(1):67-74.

101. Daley P, Thomas A, Pai M. Nucleic acid amplifi cation tests for the diagnosis of tuberculous lymphadenitis: a systematic review. Int J Tuberc Lung Dis. 2007;11(11):1166-76.

102. Riquelme A, Calvo M, Salech F, Valderrama S, Pattillo A, Arellano M, et al. Value of adenosine deaminase (ADA) in ascitic fl uid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol. 2006;40(8):705-10.

103. Steingart KR, Henry M, Laal S, Hopewell PC, Ramsay A, Menzies D, et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Thorax. 2007;62(10):911-8.

104. Shenai S, Rodrigues C, Mehta AP. Evaluation of a new phage amplifi cation technology for rapid diagnosis of tuberculosis. Indian J Med Microbiol. 2002;20(4):194-9.

105. World Health Organization, editor. Anti-tuberculosis drug resistance in the World, Report Nº4. The WHO/IUATLD Global project on anti-tuberculosis drug resistance surveillance 2002-2007. Fourth Global Report [internet]. Switzerland: WHO Press; 2009. [Consultado el 19 de Octubre de 2009]. Disponible en: www.who.int/tb/publications/2008/drs_report4_26feb08.pdf.

106. National Committee for Clinical Laboratory Standards (US). Susceptibility testing for mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. NCCLS document M24-A. National Committee for Clinical Laboratory Standards; Wayne, Pe, 2003.

107. Alcaide F, Santín M Tuberculosis multiresistente. Enferm Infecc Microbiol Clin. 2008;26(Supl 13):54-60.

108. World Health Organization, editor. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-plus [internet]. Switzerland: WHO Press; 2001. [Consultado el 19 de Octubre de 2009]. Disponible en: http://whqlibdoc.who.int/hq/2001/WHO_CDS_TB_ 2001.288.pdf.

109. Galí N, Domínguez J, Blanco S, Prat C, Quesada MD, Matas L, Ausina V. Utility of an in-house mycobacteriophage-based assay for rapid detection of rifampin resistance in Mycobacterium tuberculosis clinical isolates. J Clin Microbiol. 2003;41(6):2647-9.

110. Galí N, Domínguez J, Blanco S, Prat C, Alcaide F, Coll P, et al. Use of a mycobacteriophagebased assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and infl uence of resistance level on assay performance. J Clin Microbiol. 2006;44(1): 201-5.

111. Hardman JG, Limbrid LE, Goodman A. Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 10ª Edición. McGraw-Hill, 2001.

112. Royal Pharmaceutical Society of Great Britain, The Pharmaceutical Press (UK). Martindale: The Complete Drug Referente. 44ª Edición. Londres; 2005.

113. Thomson PDR (US). Physicians' Desk Referente. 59ª Edición. Montvale;2005.

114. World Health Organization, editor. Treatment of tuberculosis: guidelines for national programmes, 3rd ed [internet]. Switzerland: WHO Press; 2003. [Consultado el 19 de Octubre de 2009]. Disponible en: http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.313_eng.pdf.

115. World Health Organization, editor. Etambutol effi cacy and toxicity: literature review and recommendations for daily and intermittent dosage in children [internet]. Switzerland: WHO Press; 2006. [Consultado el 19 de Octubre de 2009]. Disponible en: http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.365_eng.pdf.

116. Méndez-Echevarría A, Baquero-Artigao F, García-Miguel MJ, Pascual SI, Velásquez R, del Castillo F. Visual evoked responses in children with tuberculosis treated with ethambutol. Pediatr Infect Dis. J 2007;26:92-3.

117. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62.

118. Medical Research Council. Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitations. Tubercle. 1962;43:201.

119. Bobrowitz ID, Robins DE. Ethambutol-isoniazid versus PAS-isoniazid in original treatment of pulmonary tuberculosis. Am Rev Respir Dis. 1966;96:428-38.

120. East African/British Medical Research Council. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1973;1:1331-39.

121. Short-course chemotherapy in pulmonary tuberculosis: a controlled trial by the British Thoracic and Tuberculosis Association. Lancet. 1976;2:1102-4.

122. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of fi ve 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1987;136:1339-42.

123. A controlled trial of six months chemotherapy in pulmonary tuberculosis: second report-results during the 24 months after the end of chemotherapy. British Thoracic Association. Am Rev Respir Dis. 1982;126:460-2.

124. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database of Systematic Reviews 1999,Issue4.Art.No.:CD001362.DOI: 10.1002/14651858.CD001362.

125. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364:1244-51.

126. Swaminathan S, Raghavan A, Duraipandian M, Kripasankar AS, Ramachandran P. Shortcourse chemotherapy for paediatric respiratory tuberculosis: 5-year report. Int J Tuberc Lung Dis. 2005;9(6):693-6.

127. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, Pai M, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and metaanalysis. PLoS Med. 2009;6(9):e1000146.

128. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD000970. DOI: 10.1002/14651858.CD000970.

129. Mitchison DA, Aber V, Allen BW. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet. 1981;1(8213):171-4.

130. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing Schedules of 6-Month Regimens and Relapse for Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2006;174: 1153-8.

131. Naude JMTW, Donald PR, Hussey GD, Kibel MA, Louw A, Perkins DR, Schaaf HS. Twice weekly vs. daily chemotherapy for childhood tuberculosis. Pediatr Infect Dis. J 2000;19(5): 405-10.

132. Geiter LJ, O'Brien RJ, Combs DL, Snider DE. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle. 1987;68(Suppl 2):41-6.

133. Girling DJ, Chan SL. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, threetimes weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis. 1991;143:700-6.

134. Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Curr Ther Res Clin Exp. 1996;57: 849-56.

135. Teo SK. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a fi ve-year follow-up report. Int J Tub Lung Dis. 1999;3(2):126-32.

136. Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifi nah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tub Lung Dis. 2002;6(11):1029-32.

137. Gravendeel JMT, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational fi eld study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fi xed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia.Tuberculosis. 2003;83:183-6.

138. Suryanto AA, van den Broek J, Hatta M, de Soldenhoff R, van der Werf MJ. Is there an increased risk of TB relapse in patients treated with fi xed-dose combination drugs in Indonesia? Int J Tuberc Lung Dis. 2008;12(2):174-9.

139. Bartacek A, Schütt D, Panosch B, Borek M; Rimstar 4-FDC Study Group. Comparison of a four-drug fi xed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13(6):760-6.

140. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews. 2007,Issue 4.Art. No.:CD005159. DOI: 10.1002/14651858. CD005159.pub2.

141. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An offi cial ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8): 935-52.

142. Faustini A, Hall AJ, Perucci CA. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J. 2005;26(3):503-10.

143. Ditah IC, Reacher M, Palmer C, Watson JM, Innes J, Kruijshaar ME, et al. Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective.Thorax. 2008;63(5):440-6.

144. Baussano I, Pivetta E, Vizzini L, Abbona F, Bugiani M. Predicting Tuberculosis Treatment Outcome in a Low-Incidence Area. Int J Tuberc Lung Dis. 2008;12(12):1441-8.

145. Seah G T, Scott G M, Rook G A W. Type 2 cytokine gent activation and its relationship to extent of disease in patients with tuberculosis. Clin Infect Dis. 2000;181:385-9.

146. Smego RA, Ahmed N. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int J Tuberc Lung Dis. 2003;7(3):208-13.

147. Abba K, Sudarsanam TD, Grobler L, Volmink J. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database of Systematic Reviews. 2008, Issue 4. Art. No.:CD006086. DOI:10.1002/14651858.CD006086.pub2.

148. de Bruyn G, Garner P.Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database of Systematic Reviews. 2003, Issue 1. Art. No.:CD001166. DOI: 10.1002/14651858.CD001166.

149. Vlassov VV, MacLehose HG. Low level laser therapy for treating tuberculosis. Cochrane Database of Systematic Reviews. 2006, Issue 2. Art. No.:CD003490. DOI: 10.1002/ 14651858.CD003490.pub2.

150. Roy V, Tekur U, Chopra K. Pharmacokinetics of isoniacid in pulmonary tuberculosis -a comparative study at two dose levels. Indian Pediatrics. 1996;33:287-91.

151. Engel ME, Matchaba PT, Volmink J. Corticosteroids for tuberculous pleurisy. Cochrane Database of Systematic Reviews. 2007, Issue 4. Art. No.: CD001876. DOI: 10.1002/14651858.CD001876.pub2.

152. Chapman SJ, Davies RJ. Themanagement of pleural space infections. Respirology. 2004;9(1): 4-11.

153. Loenhout-Rooyackers JH, Laheij RJ, Richter C, Verbeek AL. Shortening the duration of treatment for cervical tuberculous lymphadenitis. Eur Respir J. 2000;15(1):192-5.

154. Jawahar MS, Rajaram K, Sivasubramanian S, Paramasivan CN, Kamaludeen MN, Thirithuvathas AJ, et al. Treatment of lymph node tuberculosis - a randomized clinical trial of two 6- month regimens. Trop Med Int Health. 2005;10(11):1090-98.

155. Smith IE, Laroche CM, Jamieson SA, Shneerson JM. Kyphosis secondary to tuberculous osteomyelitis as a cause of ventilatory failure. Clinical features,mechanisms, andmanagement. Chest. 1996;110(4):1105-10.

156. Jutte PC, Van Loenhout-Rooyackers JH. Routine surgery in addition to chemotherapy for treating spinal tuberculosis. Cochrane Database of Systematic Reviews. 2006, Issue 1. Art. No.: CD004532. DOI: 10.1002/14651858.CD004532.pub2.

157. Parthasarathy R, Sriram K, Santha T, Prabhakar R, Somasundaram PR, Sivasubramanian S. Short-course chemotherapy for tuberculosis of the spine. A comparison between ambulant treatment and radical surgery - Ten-year report. J Bone Joint Surg Br. 1999;81(3):464-71.

158. Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine. Int Orthop. 1999;23:73-81.

159. Mateo L, Ruiz Manzano J, Olivé A, Manterola JM, Pérez R, Tena X, et al. [Ostearticular tuberculosis. Study of 53 cases] Med Clin (Barc). 2007;129(13):506-9.

160. Humphries M. The management of tuberculosis meningitis. Thorax. 1992;47(8):577-81.

161. Medical Research Council Report. Streptomycin treatment of tuberculous meningitis. Lancet. 1948;1:582-96.

162. Chotmongkol V. Treatment of tuberculosis meningitis with 6-month course of chemotherapy. Southeast Asian J Trop Med Public Health. 1991;22:372-374.

163. Alarcón F, Escalante L, Pérez Y, Banda H, Chacón G, Dueñas G. Tuberculous meningitis. Arch Neurol. 1990;47:1313-8.

164. Jacobs R F, Sunakorn P, Chotpitayasunonah T, Pope S, Kelleher K. Intensive short course chemotherapy for tuberculous meningitis. Pediatr Infect Dis J. 1992;11:194-8.

165. Donald PR, Schoeman JF, van Zyl LE, de Villiers JN, Pretorius M, Springer P. Intensive short course chemotherapy in the management of tuberculous meningitis. Int J Tuberc Lung Dis. 1998;2:704-711.

166. Doganay M, Calangu S, Turgut H, Bakir M, Aygen B. Treatment of tuberculous meningitis in Turkey. Scand J Infect Dis. 1995;27:135-8.

167. Phuapradit P, Vejjajiva A. Treatment of tuberculous meningitis; role of short-course chemotherapy. Quarterly J Med. 1987;239:249-58.

168. Goel A, Pandya S K, Satoskar A R. Whither short-course chemotherapy for tuberculous meningitis? Neurosurgery. 1990;27:418-21.

169. Humphries M J, Teoh R, Lau J, Gabriel M. Factors of prognostic signifi cance in Chinese children with tuberculous meningitis. Tubercle. 1990;71:161-8.

170. Ramachandran P, Duraipandian M, Nagarajan M, Prabhakar R, Ramakrishnan C V, Tripathy S P. Three chemotherapy studies of tuberculous meningitis in children. Tubercle. 1986;67:17-29.

171. Ramachandran P, Duraipandian M, Reetha A M, Mahalakshmi S M, Prabhakar R. Long-term status of children treated for tuberculous meningitis in south India Tubercle. 1989;70:235-9.

172. Sunakorn P, Pongparit S, WongrunS. Short course in tuberculous meningitis: a pilot trial. J Med Assoc Thai. 1980;63:340-5.

173. Loenhout-Rooyackers JH, Keyser A, Laheij RJ, Verbeek AL, van der Meer JW. Tuberculous meningitis: is a 6-month treatment regimen suffi cient? Int J Tub Lung Dis. 2001;5(11):1028-35.

174. Prasad K, SinghMB. Corticosteroids for managing tuberculous meningitis. Cochrane Database of Systematic Reviews. 2008, Issue 1. Art. No.: CD002244. DOI: 10.1002/14651858.CD002244.pub3.

175. Grupo de trabajo de Tuberculosis de la Sociedad Española de Infectología Pediátrica. Documento de consenso sobre el tratamiento de la tuberculosis extrapulmonar y formas complicadas de tuberculosis pulmonar. An Pediatr (Barc). 2008;69:271-8.

176. Syed FF, Mayosi BM. A modern approach to tuberculosis pericarditis. Prog Cardiovasc Dis 2007;50(3):218-36.

177. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database of Systematic Reviews. 2002, Issue 4. Art. No.: CD000526. DOI: 10.1002/14651858.CD000526.

178. Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM. 2003;96(8):593-9.

179. Reuter H, Burgess LY, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovasc J South Afr. 2006;17:233-8.

180. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticoesteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infec Dis. 1997;25:872-87.

181. World Health Organization, editor. Handbook of resolutions and decisions of the World Health Assembly and the Executive Board. Volumen III, 3ª ed. (1985-1992). Tuberculosis control programme. Geneva, World Health Organization, 1993.

182. World Health Organization, editor. Tuberculosis Programme: framework for effective tuberculosis control. Switzerland: WHO Press; 1994. [Consultado el 19 de Octubre de 2009]. Disponible en: http://whqlibdoc.who.int/hq/1994/WHO_TB_94.179.pdf.

183. World Health Organization, editor. Global tuberculosis control 2005: surveillance, planning, fi nancing [internet]. Switzerland: WHO Press; 2005. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/tb/publications/global_report/2005/en/index.html.

184. World Health Organization, editor. The STOP TB Strategy. Building on and enhancing DOTS to meet the TB-related Milleniumk Development Goals. Switzerland: WHO Press; 2005. [Consultado el 19 de Octubre de 2009]. Disponible en: http://whqlibdoc.who.int/hq/2006/WHO_HTM_STB_2006.368_eng.pdf.

185. Cox HS, Morrow M, Deutschmann PW. Long term effi cacy of DOTS regimens for tuberculosis: systematic review. BMJ. 2008;336(7642):484-7.

186. Davies GR, Squire SB. Boubts about DOTS: It's too soon to say that direct observation of short courses of tuberculosis treatment is failing. BMJ. 2008;336(7642): 457-8.

187. Frieden TR, Sbarbaro JA. Promoting adherence to treatment for tubercuoisis: the importance of direct observation. Bulletin of the World Health Organization. 2007;85(5):407-9.

188. Vernon A, for the TB Trials Consortium. TBTC Study 22 (Rifapentine Trial): Preliminary Results in HIV-negative Patients [abstract]. Am J Respir Crit CareMed. 2000; 161:A252.

189. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169-83.

190. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database of Systematic Reviews 2007; (4):CD003343. DOI: 10.1002/14651858.CD003343.pub3.

191. Liu Q, Abba K, Alejandria MM, Balanag VM, Berba RP, Lansang MAD. Reminder systems and late patient tracers in the diagnosis and management of tuberculosis. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD006594. DOI: 10.1002/14651858. CD006594.pub2.

192. Mohan A, Nassir H, Niazi A. Does routine home visiting improve the return rate and outcome of DOTS patients who delay treatment?. East Med Health J. 2003;9(4):702-8.

193. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ. 1997;315:1403-6.

194. Paramasivan R, Parthasarathy RT, Rajasekaran S. Short course chemotherapy: A controlled study of indirect defaulter retrieval method. Indian J Tuberc. 1993;40:185-90.

195. Jin BW, Kim SC, Shimao T. The impact of intensifi ed supervisory activities on tuberculosis treatment. Tubercle Lung Dis. 1993;74:267-72.

196. Morisky DE, Malotte CK, Choi P, Davidson P, Rigler S, Sugland B, et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q. 1990;17:253-67.

197. Salleras L, Alcaide J, Altet MN, Canela J, Navas E, Suñé MR, et al. Evaluation of the effi cacy of health education on the compliance with antituberculous chemoprophylaxis in school children. A randomized clinical trial. Tubercle Lung Dis. 1993;74:28-31.

198. Rusen ID, Aït-Khaled N, Alarcón E, Billo N, Bissell K, Boillot F, et al. Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome.Int J Tuberc Lung Dis. 2007;11(2):120-1.

199. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179-84.

200. Ledru S, Chauchoix B, Yameogo M, Zoubga A, Lamande-Chiron J, Portaels F et al. Impact of short-course therapy on tuberculosis drug resistance in southwest Burkina Faso. Tuber Lung Dis. 1996;77:429-36.

201. Zhang LX, Tu DH, Enarson DA. The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing. Int J Tuberc Lung Dis. 2000;4:904-10.

202. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet. 2000;355:1345-50.

203. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4(7):e238.

204. Centers for Disease Control and PreventionCDC Approaches to improving adherence to antituberculosis therapy-South Carolina and New York, 1986-1991. MMWR 1993 Feb 5; 42: 74-75.

205. Grupo de Estudio del Taller de 1999 de la Unidad de Investigación en Tuberculosis de Barcelona. Documento de Consenso sobre tratamientos directamente observados en tuberculosis. Med Clin (Barc). 2000;115:749-757.

206. Pozniak AL, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, et al. BHIVA treatment guidelines for tuberculosis TB/HIV infection 2005. HIV Med. 2005;6(Suppl 2):62-83.

207. World Health Organization, editor. Tuberculosis care with TB-HIV Co-management. Integrated Management of Adolescent and Adult Illness (IMAI). Switzerland: WHO Press; 2007. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/hiv/pub/imai/primary_tb/en/.

208. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? a retrospective cohort study in South African gold miners. J Infect Dis. 2005;191(2):150-8.

209. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodefi ciency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis. 2003;37(1):101-12.

210. Velasco M, Castilla V, Sanz J, Gaspar G, et al. Effect of Simultaneous Use of Highly Active Antiretroviral Therapy on Survival of HIV Patients With Tuberculosis. Journal Acquir Immune Defi c Syndr. 2009; 50(2):148-52.

211. Pozniak AL, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med. 2005;6(Suppl 2): 62-83.

212. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunode. Ciency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159:733-40.

213. Nahid P, González LC, Rudoy I, Jong BC, Unger A, Kawamura LM, et al. Treatment Outcomes of Patients with HIV and Tuberculosis. Am J Respir Crit Care Med. 2007;175: 1199-206.

214. Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, Rubaramira R, Mugyenyi P, Okwera A, Mugerwa R. A pilot study of antituberculosis combinations comparing rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Tuber Lung Dis. 1995;76:210-8.

215. Treating opportunistic infections among HIV-exposed and infected children. Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR. Recommendations and reports: MMWR. 2004; 53(RR-14):1-63.

216. World Health Organization, editor. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. Switzerland: WHO Press; 2006. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf.

217. Lawn SD, Bekker L-G, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet. Infect Dis 2005;5: 361-73.

218. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158: 157-61.

219. World Health Organization, editor. Guidelines for the programmatic management of drugresistant tuberculosis. Switzerland: WHO Press; 2006. [Consultado el 19 de Octubre de 2009]. Disponible en: http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf.

220. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al.Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61.

221. Faustini A, Hall AJ, Mantovani J, Sangalli M, Perucci CA, Regional group for the Survey of TB Treatment Outcomes. Treatment outcomes and relapses of pulmonary tuberculosis in Lazio, Italy, 1999-2001: a six-year follow-up study. Int J Infect Dis. 2008;12(6):611-21.

222. Picon PD, Bassanesi SL, Caramori ML, Ferreira RL, Jarczewski CA, Vieira PR. Risk factors for recurrence of tuberculosis. J Bras Pneumol. 2007;33(5):572-8.

223. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006;28(5):980-5.

224. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41(1):83-91.

225. Thomas A, Gopi PG, Santha T, Chandrasekaran V, Subramani R, Selvakumar N, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis. 2005;9(5):556-61.

226. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A Nested Case-Control Study on Treatment- related Risk Factors for Early Relapse of Tuberculosis. Am J Respir Crit Care Med. 2004;170:1124-30.

227. Hamilton CD, Stout JE, Goodman PC, Mosher A, Menzies R, Schluger NW, et al. Tuberculosis Trials Consortium.The Value of End-of-Treatment Chest Radiograph in Predicting Pulmonary Tuberculosis Relapse. Int J Tuberc Lung Dis. 2008;12(9):1059-64.

228. Millet JP, Orcau A, García de Olalla P, Casals M, Rius C, Cayla JA. Tuberculosis recurrence and its associated risk factors among successfully treated patients. J Epidemiol Community Health. 2009;63(10):799-804.

229. Fitzgerald D, Haas Dw. Mycobacterium tuberculosis. Mandel's principle. 2006. p. 2852-86.

230. Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in health care settings. Int J Tuberc Lung Dis. 2007;11(6):593-605.

231. Moro ML, Errante I, Infuso A, Sodano L, Gori A, Orcese CA, et al. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. Int J Tuberc Lung Dis. 2000;4:61-8.

232. Li Y, Leung GM, Tang JW, Yang X, Chao CY, Lin JZ, et al. Role of ventilation in airborne transmission of infectious agents in the built environment a multidisciplinary systematic review. Indoor Air. 2007;17(1):2-18.

233. Centers for Disease Control and Prevention. Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings. MMWR. 2005 Dec 30;54(RR-17): 1-141.

234. Grupo de Trabajo del área TIR de SEPAR. Recomendaciones SEPAR.Normativa sobre la prevención de la tuberculosis. Arch Bronconeumol. 2002;38(9): 441-451.

235. Behr MA, Warren SA, Salamon H, Hopewell P C, De Leon A, Daley CL, et al. Transmission of from patients smear-negative for acid-fast bacilli. Lancet. 1999;353(9151):444-9.

236. Fortun J, Martin-Davila P, Molina A, Navas E, Hermida JM, Cobo J, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother. 2007 Apr 1;59(4):794-8.

237. Blasco D, Carbó RM, González F, Momparler P, Peñuelas J A, Pérez E, et al. Guía para la vigilancia y el control de la tubeculosis. Generalitat Valenciana, Conselleria de Sanitat; 2007.

238. John Hopkins Hospital. Interdisciplionary clinical practice manual for Tuberculosis Control. 2001.

239. Rieder HL. Contacts of tuberculosis patients in high-incidence countries. Int J Tuberc Lung. 2003;7(Supl 3):S333-S336.

240. Reichler M R, Reves Randall, Bur S, Thompson V, Mangura B T, Ford J, et al. Evaluation of Investigation Conducted to Detect and Prevent Transmission of Tuberculosis. JAMA. 2002;287(8):991-5.

241. Etkind Sue C, Veen Jap. The Role of Contact tracing in tuberculosis. En: Raviglione MC, editor. Reichman and Hershfi eld's Tuberculosis. A comprehenesive, International Approach. 3era ed. New York: Informa Health Care; 2006. p. 555-77.

242. Rieder HL. Interventions for Tuberculosis Control and Elimination. Paris: International Union Against Tuberculosis and Lung Disease; 2002.

243. Morrison J, Madhukar P, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359-68.

244. Salinas Carlos, Capelastegui A., Lander Altube, España P.P., Díez Rosa, Oribe Mikel, et al. Incidencia longitudinal de la tuberculosis en una cohorte de contactos: factores asociados a la enfermedad. Arch Bronconeumol.2007;43(6):317-23.

245. Vidal R, Miravitlles M, Caylá JA, Torrela M, Martín N, De Gracia J. Estudio del contagio en 3.071 contactos familiares de enfermos con tuberculosis. Med Clin (Barc). 1997;108:361-65.

246. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med.2005;172:1169-227.

247. Grupo de Estudio de Contactos de la Unidad de Investigación en Tuberculosis de Barcelona (UITB). Documento de consenso sobre el estudio de contactos en los pacientes tuberculosos. Med Clin (Barc). 1999;112:151-156.

248. US Department of Health and Human Services, editor. Contact investigation for tuberculosis. En: Self-Study Modules on Tuberculosis [intrnet]. Atlanta;1999. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.cdc.gov/tb/education/ssmodules/pdfs/6.pdf.

249. Rufi G, García-Rodríguez JA, Solera J, Moreno S. Tuberculosis. En: Aguado JM, Almirante B, Fortín J, editores. Protocolos Clínicos de la SEIMC. Madrid: SEIMC; 2002. pág: 1-42.

250. The WHO standard tuberculin test. Geneva:World Health Organization Document; 1963. WHO/TB/Techn. Guide/3 1-19.

251. Reznik M, O.Ozuah Ph. Tuberculin Skin Testing in Children. Emerg Infect Dis. 2006;12(5): 725-8.

252. Comstock GW, Edwards LB, Philip RN, Winn WA. A comparison in the United States of America of two tuberculins, PPD-S and RT 23. Bull World Health Org. 1964; 31:161-170.

253. World Health Organization. BCG Vaccine. WHO position paper. Weekly epidemiological record 2004; 79: 27-38.

254. Cohn DL, El-Sadr W. Treatment of Latent TB Infection. En: Raviglione MC, editor. Reichman and Hershfi eld's Tuberculosis. A comprehenesive, International Approach. 3era ed. New York: Informa Health Care; 2006. p. 265-305.

255. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, et al. Transmission of Tuberculosis in New York City -- An Analysis by DNA Fingerprinting and Conventional Epidemiologic Methods. New Engl J Med. 1994;330(24):1710-6.

256. Barnes PF, Yang Z, Preston-Martin S, Pogoda JM, Jones BE, Otaya M, et al. Patterns of tuberculosis transmission in Central Los Angeles. JAMA. 1997;278(14):1159-63.

257. Sall PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, et al. The Epidemiology of Tuberculosis in San Francisco -- A Population-Based Study Using Conventional and Molecular Methods. N Eng J Med. 1994;330(24):1703-9.

258. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD000171. DOI: 10.1002/14651858.CD000171.pub2.

259. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh R C, et al. The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173:927-31.

260. Recommendations of the Advisory Council for the Elimination of Tuberculosis, CDC. Essential Components of a Tuberculosis Prevention and Control Program Screening for Tuberculosis and Tuberculosis Infection in High-Risk Populations. MMWR. 1995;44(RR-11):8-9.

261. International Union Against Tuberculosis and Lung Disease, Comittee on Prophylaxis. Effi - cacy of various durations of isoniazid preventive therapy for tuberculosis: fi ve years of followup in the IUAT trial. Bull World Health Org. 1982; 60[4]: 555-64.

262. Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA. 1986;255:1579-83.

263. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a fi nal report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827-30.

264. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non- HIV infected persons. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No.: CD001363. DOI: 10.1002/14651858.CD001363.

265. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ. 1998;31(7): 625-9.

266. Bucher HC, Griffi th L, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999 11;13(4):501-7.

267. Mohammed A, Myer L, Ehrlich R, Wood R, Cilliers F, Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis. 2007;11:1114-20.

268. Rivero A, López-Cortés L, Castillo R, Verdejo J, García MA, Martínez-Marcos FJ, et al. [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients] Enferm Infecc Microbiol Clin. 2007;25(5):305-10.

269. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid Preventive Therapy, HAART and Tuberculosis Risk in HIV-Infected Adults in South Africa: A Prospective Cohort. AIDS 2009; 23(5): 631-6.

270. Pediatric Tuberculosis Collaborative Group. Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents. Pediatrics. 2004;114:1175-201.

271. Cruz AT, Starke JR. Clinical manifestations of tuberculosis in chidren. Paediatr Respir Rev. 2007;8:107-17.

272. Spyridis N, Panayotis G, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3-and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized Study. Clin Infect Dis. 2007;45:715-22.

273. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006418. DOI:10.1002/14651858.CD006418.pub2.

274. Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334(7585):136.

275. Snider, DE, Layde PM, Johnson MW, Lyle MA.. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis. 1980;122:65-69.

276. Frieden T, Espinal M. What is the therapeutic effect and what is the toxicity of autituberculosis drugs? In: Frieden T, World Health Organization, editors. Toman's Tuberculosis.Case detection, treatment, and monitoring - questions and answers. 2ª ed. Geneva: World Health Organization 2004; 2004. p.110-21.

277. Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax. 2001;56:494-9.

278. Whittaker E, Kampmann B. Perinatal tuberculosis: new challenges in the diagnosis and treatment of tuberculosis in infants and the newborn. Early Hum Dev 2008; 84:795-9.

279. Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis. 2006;10:19-23.

280. Balcells ME, Thomas SL, Godfrey-Fausset P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744-751.

281. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada [Review article]. Int J Tuberc Lung Dis. 2008;12:1235-54.

282. Ena J, Valls V. Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysis. Clin Infect Dis. 2005;40: 670-676.

283. Page K R, Sifakis F, Montes de Oca R, Cromin W A, Doherty M C, et al. Improved Adhe rence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis. Arch Intern Med. 2006;166:1863-70.

284. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P. Treatment Completion and Costs of Randomized Trial of Rifampicin for 4 Months versus Isoniazid for 9 Months. Am J Respir Crit Care Med. 2004;170:445-9.

285. Mc Nab BD, Marciniuk DD DD, Alvi RA, Tan L, Hoeppner VH. Twice Weekly Isoniazid and Rifampin Treatment of Latent Tuberculosis Infection in Canadian Plains Aborigines. Am J Respir Crit Care Med. 2000;162(3):989-93.

286. Rennie Tw, Bothamiey GH, Engova D, Bates IP. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J. 2007;30(4):728-35.

287. Kopanoff DE, Snider DE. Isoniazid-Related Hepatitis. Am Rev Respir Dis. 1978;117:991- 1001.

288. Salpeter SR. Fatal Isoniazid-Induced Hepatitis. Its Risk During Chemoprophylaxis. West J Med. 1993;159:560-4.

289. Ormerod LP. Rifampin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child. 1998;78:169-71.

290. Center for Disease Control and Prevention (CDC), American Thoracic Society. Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003. MMWR. 2003 Aug 8;52(31):735-9.

291. Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis. 2006;10(10):1080-90.

292. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992;145(1): 36-41.

293. Lardizabal A, Passanante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130(6): 1638-40.

294. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 1997;155(5):1735-8.

295. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res. 1969;17:28-106.

296. Rose DN. Benefi ts of Screening for Latent Mycobacterium tuberculosis Infection. Arch Intern Med. 2000;160(10):1513-21.

297. Landry J, Menzies D. Preventive Chemotherapy.Where has it got us?.Where to go next? Int J Tuberc Lung Dis. 2008;12(12):1352-64.

298. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, et al. Genome plasticity of BCG and impact on vaccine effi cacy. Proc Natl Acad Sci U S A. 2007;104(13):5596-601.

299. Asociación Española de Vacunología [internet]. [actualizado en Mayo 2007, consultado el 19 de Octubre de 2009] Iglesias Gonzalo MJ. Presente y futuro de la vacuna de la tuberculosis; [10 pantallas]. Disponible en: http://www.vacunas.org.

300. Caminero Luna JA. Guía de la Tuberculosis para Médicos Especialistas. París: UICTER; 2003. [Consultado el 19 de Octubre de 2009]. Disponible en: http://www.theunion.org.

301. Pereira S. BCG against tuberculosis, its protective effect and vaccination policies. Rev Saude Publica. 41[Suppl 1]. 2007.

302. Brewer TF. Preventing Tuberculosis with Bacillus Calmette-Guerin Vaccine: A Meta-Analysis of the Literature. Clin Infect Dis. 2000;31(s3):S64-S67.

303. Bourdin Trunz B, Fine PEM, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet. 2006;367:1173-80.

304. Manissero D, Lopalco PL, Levy-Bruhl D Ciofi Degli Atti ML, Giesecke J. Assessing the impact of different BCG vaccination strategies on severe childhood TB in low-intermediate prevalence settings. Vaccine. 2008;26(18):2253-9.

305. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Effi cacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271(9):698-702.

306. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The Effi cacy of Bacillus Calmette-Guerin Vaccination of Newborns and Infants in the Prevention of Tuberculosis: Meta-Analyses of the Published Literature. Pediatrics. 1995;96(1):29-35.

307. Hersh AL, Tala-Heikkilä M, Tala E, Tosteson AN, Fordham von Reyn C A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland. Int J Tuberc Lung Dis. 2003;7(1):22-9.

308. Sterne JAC, Rodrigues L.C, Guedes N. Does the effi cacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis. 1998;2(3):200-7.

309. Hart PD, Sutherland I. BCG and Vole Bacillus Vaccines in the prevention of tuberculosis in adolescence and early adult life: Final report to the Medical Research Council. BMJ. 1977;2: 293-5.

310. Barreto M, Pereira S, Ferreira A. BCG vaccine: effi cacy and indications for vaccination and revaccination. J Pediatr (Rio J). 2006;82[3]:S45-54.

311. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet. 1996;348:17-24.

312. Barreto ML, Rodrigues LC, Cunha SS, Pereira S, Hijjar MA, Ichihara MY, et al. Design of the Brazilian BCG REVAC trial against tuberculosis: a large, simple randomized community trial to evaluate the impact on tuberculosis of BCG revaccination at school age. Control Clin Trials. 2002;23:540-53.

313. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCGREVACcluster-randomised trial. Lancet. 2005;366:1290-5.

314. Diel R, Seidler A, Nienhaus A, Rusch-Gerdes S, Niemann S. Occupational risk of tuberculosis transmission in a low incidence area. Respir Res 2005;6(1):35.

315. Lotte A, Wasz-Hoockert O, Poisson N, Dumitrescu N, Verron M. Complicaciones ocasionadas por la vacunación BCG: Estudio retrospectivo. Bull Unión Int Tuber (ed. español). 1980;55: 57-66.

316. Lotte A, Wasz-Hoockert O, Poisson N, Engbaek H, Landmann H, Quast U, et al. Segundo estudio de la UICTER sobre las complicaciones de la vacunación intradérmica con BCG. Bull Union Int Tuberc (ed español). 1988, 63: 51-63.

317. Martín Montañes C, Iglesias Gozalo MJ, Altet Gómez MN. Tuberculosis. En: Asociación Española de Pediatría, editor. Manual de Vacunas en Pediatría (4ª edición); 2008. p. 583-97.

318. Hawkridge A, Hatherill M, Little F, Goetz MA, Barker L, Mahomed H, et al. Effi cacy of Percutaneous versus Intradermal BCG in the Prevention of Tuberculosis in South African Infants: Randomised Trial. BMJ. 2008;337:a2052.doi: 10.1136/bmj.a2052.

319. World Health Organization, editor. Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs [internet]. Switzerland: WHO Press; 1997. [consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/tb/publications/tb_compendium_of_indicators/en/.

320. World Health Organization, editor. Implementing the WHO Stop TB Strategy: A Handbook for national tuberculosis control programmes [internet]. Switzerland: WHO Press; 2008. [consultado el 19 de Octubre de 2009]. Disponible en: http://www.who.int/tb/publications/2008/who_htm_tb_2008_401_eng.pdf.

321. Rodrigo T, Caylà JA, Galdós-Tangüis H, García de Olalla P, Brugal MT, Jansà JM. Proposing indicators for evaluation of tuberculosis control programmes in large cities based on the experience of Barcelona. Int J Tuberc Lung Dis. 2001;5(5):432-40.


Última actualización: febrero 2011

Logo del Ministerio de Ciencia e InnovaciónLogo del Ministerio de Sanidad y Consumo Logo del Plan de Calidad del Sistema Nacional de SaludAgència d’Avaluació de Tecnologia i Recerca Mèdiques de Cataluña

 

Copyright | Ayuda | Mapa